144 related articles for article (PubMed ID: 35307978)
21. PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes.
Cho CK; Ko E; Mo JY; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 Jan; 47(1):82-94. PubMed ID: 38150171
[TBL] [Abstract][Full Text] [Related]
22. A pharmacokinetic model of drug-drug interaction between clopidogrel and omeprazole at CYP2C19 in humans.
Tangamornsuksan W; Thiansupornpong P; Morasuk T; Lohitnavy O; Lohitnavy M
Annu Int Conf IEEE Eng Med Biol Soc; 2017 Jul; 2017():2704-2707. PubMed ID: 29060457
[TBL] [Abstract][Full Text] [Related]
23. Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y
Zhang Y; Zhu X; Zhan Y; Li X; Liu C; Zhu Y; Zhang H; Wei H; Xia Y; Sun H; Liu Y; Lai X; Gong Y; Liu X; Li Y; Ding Y; Zhong D
Br J Clin Pharmacol; 2020 Sep; 86(9):1860-1874. PubMed ID: 32267573
[TBL] [Abstract][Full Text] [Related]
24. Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
Liu S; Wang Z; Tian X; Cai W
Front Pharmacol; 2020; 11():591854. PubMed ID: 33424602
[TBL] [Abstract][Full Text] [Related]
25. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
[TBL] [Abstract][Full Text] [Related]
26. Modeling of Hepatic Drug Metabolism and Responses in CYP2C19 Poor Metabolizer Using Genetically Manipulated Human iPS cells.
Deguchi S; Yamashita T; Igai K; Harada K; Toba Y; Hirata K; Takayama K; Mizuguchi H
Drug Metab Dispos; 2019 Jun; 47(6):632-638. PubMed ID: 30962288
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.
Horenstein RB; Madabushi R; Zineh I; Yerges-Armstrong LM; Peer CJ; Schuck RN; Figg WD; Shuldiner AR; Pacanowski MA
J Clin Pharmacol; 2014 Aug; 54(8):865-73. PubMed ID: 24710841
[TBL] [Abstract][Full Text] [Related]
28. Association of CYP2C19*2 polymorphism with clopidogrel resistance among patients with high cardiovascular risk in Northeastern Mexico.
Cedillo-Salazar FR; Martínez-Jacobo L; Pérez-Páramo YX; Cerda-Flores R; Martínez LE; Jaime-Pérez JC; Moreno-Treviño MG; Pérez-Rodríguez E; Bosques-Padilla FJ; Cedillo-Avila M; Cedillo-Avila MA; Zamudio-Osuna M
Arch Cardiol Mex; 2019; 89(4):324-329. PubMed ID: 31834317
[TBL] [Abstract][Full Text] [Related]
29. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.
Shebley M; Fu W; Badri P; Bow D; Fischer V
Clin Pharmacol Ther; 2017 Oct; 102(4):679-687. PubMed ID: 28411400
[TBL] [Abstract][Full Text] [Related]
30. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
[TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
[TBL] [Abstract][Full Text] [Related]
32. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
McDonough CW; McClure LA; Mitchell BD; Gong Y; Horenstein RB; Lewis JP; Field TS; Talbert RL; Benavente OR; Johnson JA; Shuldiner AR
J Am Heart Assoc; 2015 May; 4(6):e001652. PubMed ID: 26019129
[TBL] [Abstract][Full Text] [Related]
33. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA;
J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483
[TBL] [Abstract][Full Text] [Related]
34. The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention.
Ayesh BM; Al-Astal IR; Yassin MM
Int J Clin Pharm; 2019 Feb; 41(1):96-103. PubMed ID: 30656556
[TBL] [Abstract][Full Text] [Related]
35. Body weight, CYP2C19, and P2Y12 receptor polymorphisms relate to clopidogrel resistance in a cohort of Chinese ischemic stroke patients with aspirin intolerance.
Li Z; Dong W; Yang D; Sun L; He X; Hu H; Zhang J; Wang C; Li Y; Zhao M; Kong Y; Wang Y
Eur J Clin Pharmacol; 2020 Nov; 76(11):1517-1527. PubMed ID: 32632713
[TBL] [Abstract][Full Text] [Related]
36. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
[TBL] [Abstract][Full Text] [Related]
37. Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite.
Boulenc X; Djebli N; Shi J; Perrin L; Brian W; Van Horn R; Hurbin F
Drug Metab Dispos; 2012 Jan; 40(1):187-97. PubMed ID: 22004687
[TBL] [Abstract][Full Text] [Related]
38. Dosage optimization of clopidogrel via a precision medicine approach: the way forward.
V Aswathy SP; Chandra KR; Jyothikrishna P; Arun KP
Pharmacogenomics; 2022 Feb; 23(3):195-206. PubMed ID: 35112572
[TBL] [Abstract][Full Text] [Related]
39. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
[TBL] [Abstract][Full Text] [Related]
40. Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study.
Yu L; Wang T; Bai H; Zhu W; Li Y; Wu J; Liu W; Sun L; Yu A; Li H
BMC Cardiovasc Disord; 2021 Aug; 21(1):391. PubMed ID: 34384383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
